Profile
Joseph Wilkinson currently works at Nanomosaic Inc., as President & Chief Operating Officer from 2023.
Joseph Wilkinson active positions
Companies | Position | Start |
---|---|---|
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | President | 06/12/2023 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | Commercial Services |
- Stock Market
- Insiders
- Joseph Wilkinson